Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

Inclusion Criteria: * Patients younger than 24 weeks. * Presenting a hemangioma with the following characteristics: * Subcutaneous and/or cutaneous * Minimum diameter of 1.5 cm on face, 3 cm outside face and 1.5 cm if it is ulcerated. * Consent of both parents (or the person having parental authority in families) Exclusion Criteria: * Infant presenting contraindications for the administration of propranolol or atenolol. * Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments. * Patients with an inability to participate or to follow the study treatment and assessment plan.